



**PHARMACY AND POISONS BOARD  
HONG KONG**  
香港藥劑業及毒藥管理局

Your Ref. :  
貴處檔號

Our Ref. : DH DO PRIE/1-55/1  
本局檔號

Tel. No. : 3974 4133  
電話

Fax No. : 2803 4962  
圖文傳真

C/O Drug Office  
Suites 2002-05, 20/F, AIA Kowloon Tower,  
Landmark East, 100 How Ming Street,  
Kwun Tong, Kowloon, Hong Kong  
香港九龍觀塘巧明街100號  
Landmark East 友邦九龍大樓  
20樓2002-05室

28<sup>th</sup> June 2021

To: Certificate holders of  
registered pharmaceutical products

Dear Sir / Madam,

**New Warnings for Vascular Endothelial Growth Factor (VEGF) Pathway  
Inhibitors**

On 24<sup>th</sup> June 2021, the Pharmacy and Poisons (Registration of Pharmaceutical Products and Substances: Certification of Clinical Trial/Medicinal Test) Committee (the Committee) considered the latest new warnings for pharmaceutical products for systemic administration containing VEGF pathway inhibitors (excluding those administered intravitreally) by the drug regulatory authorities of Australia, Canada, European Union, Singapore, United Kingdom and United States and decided that the sales pack labels and / or package inserts of such products should include the following new safety information (or equivalent):

***“ Special warnings and precautions for use***

***Aneurysms and artery dissections***

*The use of VEGF pathway inhibitors in patients with or without hypertension may promote the formation of aneurysms and/or artery dissections. Before initiating [Product Name / Generic Name], this risk should be carefully*

*considered in patients with risk factors such as hypertension or history of aneurysm.*

***Undesirable effects***

*Aneurysms and artery dissections are listed as adverse reactions under vascular disorders with frequency "not known".*

You are therefore required to review and revise, if necessary, the sales pack labels and / or package inserts of the concerned products registered by your company to ensure that the products comply with the above new requirements. The revised sales pack labels and / or package inserts should be submitted to the Committee for approval within 2 months from the date of this letter. Failing to comply with the above requirements may result in de-registration of the products or registration not renewed by the Committee.

If you have any enquiries on the above issue, please contact Ms. Queenie CHAN at 3974 4147.

Yours faithfully,



(T.K. YIM)

Secretary,

Pharmacy and Poisons (Registration of  
Pharmaceutical Products and Substances:  
Certification of Clinical Trial/Medicinal Test)  
Committee

c.c. 7-15/3, Product Files

TK/QC